DocDollars

Kiniksa Pharmaceuticals, Ltd.

Bermuda · Reporting entity ID 100000846825

Total reported 2019–2025
$8.39M
#551 of 2,960 reporting companies — 0% of all reported industry payments
$1.38M in general payments across 20,352 records, plus $7.01M in research funding across 5,070 records.

How it breaks down

General payments $1,375,932
Research funding $7,011,923

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Kiniksa Pharmaceuticals, Ltd. reported $8.39M to US doctors and teaching hospitals from 2019 to 2025, ranking #551 of 2,960 reporting companies. 84% of that was research funding and 16% general payments such as consulting, speaking, food and travel. 20,352 general payment records and 5,070 research records were filed.

Common questions about Kiniksa Pharmaceuticals, Ltd.

How much has Kiniksa Pharmaceuticals, Ltd. paid US doctors?

Kiniksa Pharmaceuticals, Ltd. reported $8,387,855 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $1,375,932 in general payments, $7,011,923 in research funding.

How does Kiniksa Pharmaceuticals, Ltd. rank among drug and device companies?

It ranks #551 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Kiniksa Pharmaceuticals, Ltd. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.